ONXX Related Analyst Ratings
-
Brean Capital Raises Onyx (ONXX) Price Target to $115
-
Jefferies Lifts PT on Onyx Pharmaceuticals (ONXX) to $104
-
Jefferies Positive on Onyx Pharmaceuticals (ONXX) after NCCN Compendia Listing For Frontline Kyprolis
-
Jefferies Trims PT on Onyx Pharmaceuticals (ONXX) Post Q4
-
JMP Securities Starts Onyx Pharmaceuticals (ONXX) at Market Outperform
-
Approval of Celgene's (CELG) Pomalyst Largely Expected by Street (ONXX)
-
Onyx Pharma's (ONXX) Kyprolis 'Killin It'
-
UBS Starts Onyx Pharmaceuticals (ONXX) at Buy
-
Onyx Pharmaceuticals (ONXX) May Have Untapped Opportunity in Frontline Multiple Myeloma
-
Dawson James Starts Onyx Pharmaceuticals (ONXX) at Market Outperform
-
Baird Slaps $99 Price Target on Onyx Pharmaceuticals (ONXX)
-
UPDATE: Canaccord Genuity Assumes Onyx Pharmaceuticals (ONXX) at Buy
-
Brean Murray Carret & Co. Assumes Onyx Pharmaceuticals (ONXX) at Buy, Kyprolis is Key
-
Baird Reiterates an 'Outperform' on Onyx Pharmaceuticals (ONXX); Raising Kyprolis Estimates
-
Onyx's (ONXX) Myeloma Drug Might be used for Earlier Stage Treatments
-
Jefferies Reiterates a 'Buy' on Onyx Pharmaceuticals (ONXX); Predicting Strong Kyprolis Launch
-
Onyx Pharmaceuticals (ONXX) Is Trading at Pre-Kyprolis Approval Levels; Is It Time to Buy?
-
Griffin Securities Reiterates a 'Buy' on Ligand Pharma (LGND); Investors Jumped The Gun...Attractive Opportunity
-
Baird Reiterates an 'Outperform' on Onyx Pharmaceuticals (ONXX); Kyprolis Uptake and Take-out Potential
-
Baird Reiterates an 'Outperform' on Onyx Pharmaceuticals (ONXX); FDA approval of Kyprolis and Increased Takeover Chatter
-
Bernstein Downgrades Onyx Pharma (ONXX) to Market Perform
-
Cantor Fitzgerald Maintains a 'Buy' on Ligand Pharma (LGND); Key Partnered Drug is Approved
-
Deutsche Bank Maintains a 'Buy' on Onyx Pharmaceuticals (ONXX); SEARCH Fails, But Success Wasn't Necessary
-
Jefferies Upgrades Onyx Pharmaceuticals (ONXX) to Buy; FDA Approves Kyprolis; Takeover Speculation Intensifies
-
Barclays Upgrades Onyx Pharmaceuticals (ONXX) to Overweight
-
UPDATE: Onyx Pharma (ONXX) Shares Rise as Leerink Swann Upgrades to Outperform
-
Deutsche Bank Sees $21 of Upside in Onyx (ONXX) Shares If Kyprolis Pricing Inline with Velcade
-
Deutsche Bank Reiterates a 'Buy' on Onyx Pharmaceuticals (ONXX); Expert Weigh In on DECISION
-
Brean Murray Raises PT on Onyx Pharma (ONXX); FDA Grants Regorafenib Priority Review; Takeout Speculation Looms
-
Deutsche Bank Raises Price Target on Onyx Pharmaceuticals (ONXX); Adding M&A Scenario
-
Morgan Stanley Upgrades Onyx Pharmaceuticals (ONXX) to Equalweight
-
Barclays Raises Price Target on Onyx Pharmaceuticals (ONXX); Kyprolis Gets Surprisingly Supportive Commentary
-
Jefferies Adjusts Estimates and Price Target on Onyx Pharmaceuticals (ONXX); Downside Scenarios Reviewed
-
Cowen Upgrades Onyx Pharmaceuticals (ONXX) to Outperform
-
Brean Murray Carret & Co. Upgrades Onyx Pharmaceuticals (ONXX) to Buy; Misleading Documents...FDA Approval Is Coming
-
Baird Upgrades Onyx Pharmaceuticals (ONXX) to Outperform
-
Deutsche Bank Starts Onyx Pharmaceuticals (ONXX) at Buy; Kyprolis Has Blockbuster Potential
-
Goldman Sachs Raises Price Target on Onyx Pharma (ONXX) after FDA Panel Backs CFZ
-
Baird Maintains a 'Neutral' on Onyx Pharmaceuticals (ONXX); Continue Warming Up To Kyprolis
-
BofA/Merrill Lynch Upgrades Onyx Pharmaceuticals (ONXX) to Buy
-
Jefferies Said Onyx Pharmaceuticals (ONXX) ASCO Data Confirm Concerns On Carf Regulatory Outlook
-
Bernstein Starts Onyx Pharmaceuticals (ONXX) at Outperform
-
Baird Reiterates a 'Neutral' on Onyx Pharmaceuticals (ONXX); Nexavar Miss Not Real Issue; Kyprolis Remains Focus
-
Barclays Maintains an 'Equalweight' on Onyx Pharmaceuticals (ONXX); Facing Uphill Battle
-
Goldman Sachs Removes Onyx Pharmaceuticals (ONXX) from Conviction Buy List
-
Barclays Maintains an 'Equalweight' on Onyx Pharmaceuticals (ONXX); $4 Upside if MISSION Works
-
Rodman & Renshaw Says Onyx (ONXX) Shares Undervalued; Reiterates Outperform, $57 Price Target
-
Canaccord Genuity Maintains a 'Buy' on Onyx Pharmaceuticals (ONXX); Year-end Nexavar Sales Beat
-
Morgan Stanley Starts Onyx Pharmaceuticals (ONXX) at Underweight
-
Canaccord Genuity on Life Sciences/Biotechnology: Forex Exposure - Impact ITMN, PLX, AEGR & ONXX
Back to ONXX Stock Lookup
